Company Description
Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function.
The company’s lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney disease receiving hemodialysis.
It also develops Next Gen ERT for the treatment of ossification of the posterior longitudinal ligament (OPLL); and Gene therapy, a disease of the PPi-Adenosine Pathway.
The company has license agreement with Yale University for specified therapeutic and prophylactic products.
Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts. As of July 1, 2025, Inozyme Pharma, Inc. operates as a subsidiary of BioMarin Pharmaceutical Inc..
| Country | United States |
| Founded | 2015 |
| IPO Date | Jul 24, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 67 |
| CEO | Douglas Treco |
Contact Details
Address: 321 Summer Street Boston, Delaware 02210 United States | |
| Phone | 857 330 4340 |
| Website | inozyme.com |
Stock Details
| Ticker Symbol | INZY |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001693011 |
| CUSIP Number | 45790W108 |
| ISIN Number | US45790W1080 |
| Employer ID | 47-5129768 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Douglas A. Treco Ph.D. | Chief Executive Officer and Chairman |
| Axel Bolte M.B.A., M.Sc. | Co-Founder, Senior Advisor and Director |
| Sanjay S. Subramanian M.B.A., M.S. | Chief Financial Officer, Head of Business Development, Principal Accounting Officer and Corporate Secretary |
| Dr. Matthew Winton Ph.D. | Senior Vice President and Chief Operating Officer |
| Dr. Demetrios Braddock M.D., Ph.D. | Co-Founder, Scientific Founder, Member of Scientific Advisory Board and Board Observer |
| Dr. Yves Sabbagh Ph.D. | Senior Vice President, Chief Scientific Officer and Chair of the Scientific Advisory Board |
| Stefan Riley | Director of Investor Relations |
| Gayle Gironda | Senior Vice President and Chief People Officer |
| Stephen J. Di Palma M.B.A. | Consultant |
| Dr. Petra Duda M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 1, 2025 | EFFECT | Notice of Effectiveness |
| Jul 1, 2025 | EFFECT | Notice of Effectiveness |
| Jul 1, 2025 | 25-NSE | Filing |
| Jul 1, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jul 1, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jul 1, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jul 1, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jul 1, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jul 1, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jul 1, 2025 | POS AM | Post-Effective amendments for registration statement |